Nuwellis, Inc.

Nuwellis, Inc. is a medical technology company dedicated to precision fluid management and ultrafiltration therapy. Headquartered in Eden Prairie, Minnesota, with a wholly owned subsidiary in Ireland, the company's mission is to transform the lives of patients suffering from fluid overload by advancing technologies that ensure measurable, controllable, and consistent fluid balance across acute and chronic care settings.

The company's core products are the Aquadex FlexFlow and Aquadex SmartFlow systems, medical devices utilized in ultrafiltration therapy. These systems are designed to remove excess fluid from adult and pediatric patients (weighing 20 kg or more) with cardiorenal conditions, including heart failure and acute kidney injury, particularly when fluid overload is unresponsive to traditional medical management like diuretics. Nuwellis focuses on market segments such as critical care, pediatrics, nephrology, cardiology, and hospital-based outpatient therapy, distributing its products to hospitals and clinics through a direct salesforce in the United States and specialty distributors internationally.

In recent leadership changes, Mike McCormick was appointed Chief Executive Officer, effective June 30, 2026, succeeding John Erb, who will continue as Chairman of the Board. The company recently executed a 35-for-1 reverse stock split to maintain compliance with stock exchange listing requirements and completed a $6.0 million public offering. Nuwellis is actively expanding its pediatric program, including new installations in Michigan, and reported a 26% year-over-year revenue increase in the first quarter of 2026.